Emerging role of histone and non-histone lactylation in metabolic reprogramming of female-specific malignancies Authors: Cheng Sun, Dan Hu, Wei Peng, Zhaolei Cui, Yingying Lin Published: 2025 ABSTRACT AbstractLysine lactylation (Klac), a recently characterized post-translational modification, has emerged as a critical epigenetic regulator in female-prevalent malignancies including breast, ovarian, cervical, and endometrial cancers. Emerging evidence from recent studies demonstrates that both histone and non-histone Klac modifications exert oncogenic effects through multifaceted mechanisms: orchestrating transcriptional reprogramming, redirecting metabolic flux, reshaping immune microenvironments, and potentiating malignant phenotypes in cellular proliferation, migration, and invasion. The dynamic landscape of Klac patterns shows promise as a dual-purpose biomarker platform, potentially enabling both early detection and prognostic stratification in these hormone-related malignancies. Current investigations further highlight therapeutic opportunities through targeting Klac-associated pathways, particularly in developing precision interventions against therapy-resistant tumor subtypes. This comprehensive review meticulously scrutinizes the expression profiles, functional ramifications, and molecular interactions within histone and non-histone protein Klac networks in breast and gynecological cancers, while rigorously assessing their translational potential. Future investigations should prioritize three critical standardizing lactylation detection methodologies for clinical specimens and elucidating its systems-level interplay with other epigenetic regulators. Concurrently, rigorous preclinical validation of Klac-targeting compounds remains imperative to propel therapeutic innovation.Keywords: Lysine lactylation, Female prevalent malignancies, Breast cancer, Ovarian cancer, Cervical cancer, Endometrial cancer, Mechanism Introduction Breast, ovarian, cervical, and endometrial cancers, constituting the four most prevalent malignancies of the female reproductive system, impose a significant global disease burden and rank prominently among the primary causes of cancer-related mortality in women [1–4]. According to the 2021 WHO Global Cancer Statistics report, these malignancies collectively account for 38.6% of new cancer cases in women worldwide, with breast cancer dominating at 2.3 million cases (24.5% of female cancers), followed by cervical (604,000 cases) and endometrial cancers (417,000 cases) [5]. In terms of mortality, breast cancer remains the foremost cause of cancer-related deaths in women, while ovarian cancer ranks eighth, with 5-year survival rates for advanced stages persistently below 40% [5, 6]. Notably, epidemiologic profiles exhibit marked geographic heterogeneity: endometrial cancer incidence in high-income countries continues to rise in parallel with obesity epidemics, whereas cervical cancer mortality remains disproportionately high in low- and middle-income regions (LMICs), where HPV vaccination coverage remains suboptimal (< 20%) [7, 8]. These disparities underscore the urgent need for targeted public health interventions to address these critical women’s health challenges. Despite advancements in conventional therapies, such as chemotherapy, immunotherapy, and targeted treatments, which have somewhat improved patient outcomes, managing these malignancies continues to present critical challenges [9]. Key limitations include tumor cell drug resistance, the paucity of clinically actionable molecular targets, and diminished therapeutic efficacy in advanced stages due to suboptimal drug delivery and intervention strategies [10–12]. Recent advances in protein post-translational modification (PTM) research have catalyzed a paradigm shift in gynecologic oncology biomarker development, transitioning from single-protein analyses to dynamic monitoring of modification-specific markers with enhanced dimensionality, temporal resolution, and specificity. Lysine lactylation (Klac), an emerging PTM, has garnered increasing attention since its discovery [13–15]. In a groundbreaking study conducted in 2019, Zhao’s team at the University of Chicago identified histone Klac as a novel epigenomic regulatory mechanism fueled by lactate, a metabolic byproduct of glycolysis, which critically influences transcriptional activity [15]. Lactylation exclusively targets lysine residues [16], with histones serving as primary substrates [17–19]. Cellular lactate levels, tightly coupled to glycolytic flux, directly regulate this modification [15]. Hypoxic conditions or Warburg effect-driven aerobic glycolysis in tumor cells markedly accelerate lactate production [20–23], which subsequently donates “lactyl” groups for protein modification, thereby reprogramming cellular functions [24]. Accumulating evidence suggests a pivotal role for Klac in oncogenic processes, including metabolic reprogramming, proliferation, invasion, and metastasis, across multiple malignancies [25–28], offering fresh insights into tumorigenesis. In breast and gynecologic cancers, elucidating the molecular mechanisms and biological consequences of Klac may unveil novel diagnostic biomarkers and therapeutic targets, potentially revolutionizing management strategies to improve survival outcomes and quality of life for patients. This review aims to systematically delineate the multifaceted roles of Klac in female-specific cancers, with a primary focus on breast, ovarian, cervical, and endometrial malignancies. We will critically evaluate the current understanding of Klac’s functional implications in tumor progression, dissect the underlying molecular mechanisms, particularly its involvement in metabolic reprogramming and epigenetic regulation, and assess its emerging clinical relevance as a potential diagnostic and prognostic biomarker. A key novelty of this work is its comprehensive synthesis of Klac’s pathophysiological significance across gynecologic oncology. By integrating disparate findings into a cohesive framework, this review addresses a critical knowledge gap and highlights Klac’s therapeutic targeting potential, thereby establishing a foundational resource for future research and therapeutic development in this rapidly evolving field. Regulation of lactate production and Klac Lactate, a key metabolic byproduct with essential physiological functions, is primarily generated under normoxic conditions through lactate dehydrogenase (LDH)-mediated reduction of pyruvate [29]. It is subsequently oxidized for energy production or utilized as a gluconeogenic precursor via the lactate shuttle mechanism [30]. In the tumor microenvironment (TME), lactate accumulates extensively due to metabolic reprogramming, where cancer cells preferentially rely on glycolysis over oxidative phosphorylation for energy production even under oxygen-sufficient conditions—a phenomenon termed the Warburg effect [19, 31, 32]. This glycolytic shift, observed in malignancies, bacterial infections, and M1 macrophage polarization, drives lactate overproduction through upregulation of key enzymes such as LDH, which catalyzes pyruvate-to-lactate conversion [15]. The resulting lactate pool serves as the substrate for Klac [15]. Lactate can be conjugated with coenzyme A (CoA) under the catalysis of certain ATP-dependent enzymes (e.g., acetyl-CoA synthetase 2, ACSS2), forming the high-energy donor lactyl-CoA. This process represents a critical step in Klac modification, providing both energy and reactive intermediates for subsequent lactyl group transfer [33]. Klac is characterized by the covalent conjugation of a lactate-derived lactyl group to the ε-amino group of a lysine residue, forming a stable lactyl-lysine adduct on substrate proteins such as histones [15]. This process is catalyzed by lactyltransferases (e.g., p300, KAT2A) and exhibits metabolic dependency, with modification levels positively correlating with intracellular lactate concentrations [15, 24, 33, 34]. The dynamic equilibrium of Klac is regulated by opposing enzymatic activities: “writers” (p300/CBP, KAT2A, TIP60) mediate lactyl group addition, while “erasers” (SIRT1/SIRT2, HDAC1/HDAC3) catalyze their removal [34]. Histone deacetylases (HDAC1-3), for instance, counteract Klac by cleaving lactyl groups, restoring unmodified histones and maintaining modification plasticity [35]. As a paradigm of Klac, histone Klac (e.g., H3K18lac, H4K8lac) predominantly localizes to promoter regions of transcriptionally active genes [15]. Mechanistically, histone acetyltransferases (HATs) like KAT2A exhibit lactyltransferase activity, transferring lactyl groups from lactyl-CoA to specific lysine residues. For example, ACSS2 synthesizes lactyl-CoA, which cooperates with p300/CBP to deposit H3K18lac modifications, thereby modulating chromatin accessibility, transcriptional activation, and tumor immune evasion [33]. This Klac-driven chromatin remodeling alters nucleosome architecture, influencing transcriptional programs that underpin pathological processes such as metabolic adaptation and immune escape in malignancies [33]. Histone lactylation represents a prototypical example of Klac modifications, with its core mechanistic framework illustrated in Fig. 1. Other Klac regulators/factors are summarized in Table 1. Key steps in histone Klac modification. A The Warburg effect has been observed across diverse biological systems, including both prokaryotic and eukaryotic organisms. This metabolic pathway is characterized by the cellular preference for converting glucose to pyruvate via glycolysis, which is subsequently reduced to lactate, even under oxygen-sufficient conditions, thereby facilitating rapid energy production and the accumulation of biosynthetic precursors. B The lactate generated during the Warburg effect serves as the fundamental substrate for Klac. It is first activated to form the high-energy donor lactyl-CoA, a reaction catalyzed by certain ATP-dependent enzymes such as ACSS2. This lactyl-CoA then acts as the direct co-substrate for lactate transferases, which catalyze the covalent modification of lysine residues on target proteins. C The Klac modification occurs when lactyl-CoA transfers its “lactyl-” group to specific lysine residues on histones (e.g., H3K18lac) and non-histone proteins. Catalyzed by lactyltransferases (“writers”) such as p300 and KAT2A, this process is metabolically dependent, with its levels directly influenced by fluctuating intracellular lactate concentrations. D The removal of Klac is catalyzed by “eraser” enzymes, including histone deacetylases (HDACs). A key mechanism involves HDAC1 to HDAC3, which remove the lactyl group from lactylated histones (e.g., H3K18lac), reverting them to the unmodified state and thereby maintaining epigenetic plasticity. Klac lysine lactylation, ACSS2 Acetyl-CoA synthetase 2, H3K18lac Histone H3 lysine 18 lactylation, p300 EP300 lysine acetyltransferase, KAT2A Lysine acetyltransferase 2 A Table 1Current evidence on protein Klac modifications in prevalent female malignanciesCancer typeKey findings and clinical implicationsKlac proteinsKlac regulatorsKlac-modulating proteins/pathwaysBreast cancer(1) Protein Klac plays a pivotal role in breast cancer pathogenesis by modulating tumor progression, clinical prognosis, and immune microenvironment dynamics; (2) Prognostic models can be established based on Klac-associated genetic signatures or biomarkersH4K12lac [55, 60];H3K18lac[59]; SLFN5[60];CCR7, IGFBP6, NDUFAF6[57]ACAA2[87]KCNK1[59], LDHA[59]; DCA/sodium oxamate[60];LDHC4[61]c-MYC/SRSF10/MDM4-FL/BCL-XL [58]; ANLN/EZR/stiffness/adhesion[59]; SLFN5[60]ACAA2/FFA/Cell cycle/PI3K-AKT-mTOR-medicated autophagy[61]Ovarian cancer(1) Klac-associated genes serve as prognostic biomarkers, modulating immune evasion and TEM remodeling; (2) Elevated H3K18lac levels correlate with adverse clinical outcomes.SNRPA1, MPHOSPH6, POLDIP3, RB1, AHNAK, MAGOHB, CALM1, EP300, HDAC1, HDAC2, HDAC3, SIRT1, SIRT2, and SIRT3 [63]; PFKP (K392la) [69]; H3K18lac [66, 68, 70]LDHB[66]; Tanshinone I [70]CCL18[68]; PD-L1[66]; PTEN[69]Cervical cancer(1) Protein lactylation drives cervical cancer progression through multiple mechanisms, including TEM modulation; (2) Lactylation-associated molecular signatures enable the development of prognostic prediction models.DCBLD1[71], G6PD-K45lac[72], H3K18lac[52], PPP1R14B-K140lac[73]Lactate [52] [71]; HPV16 E6/PPP[72]GPD2 [52], CD86/iNOS/CD206/Arg-[52]; PPP/HIF-1α/G6PD/autophagy [71]; GSH/NADPH/ROS [72]; infiltration of CD8+ T cells[73]Endometrial cancer(1) Elevated protein lactylation characterizes endometrial carcinoma and functionally contributes to malignant phenotypes; (2) Targeting lactylation effectively inhibits tumor cell proliferation and migration; and (3) The oncoprotein USP39 exerts its pro-tumor effects via PI3K/AKT-mediated HIF-1α activationH3K18lac[74]2-DG [74], oxamate [74]USP39[74], PI3K/AKT/HIF-1α [74], PGK1/GLUT-1/HK2/LDHA [74]TEM Tumor microenvironment, Klac Lysine lactylation, H4K12lac Histone H4 lysine 12 lactylation, H3K18lac Histone H3 lysine 18 lactylation, SLFN5 Schlafen family member 5, CCR7 C-C motif chemokine receptor 7, IGFBP6 Insulin like growth factor binding protein 6, NDUFAF6 NADH Ubiquinone oxidoreductase complex assembly factor 6, ACAA2 Acetyl-CoA acyltransferase 2, KCNK1 Potassium two pore domain channel subfamily K member 1, LDHA Lactate dehydrogenase A, DCA Dichloroacetate, LDHC Lactate dehydrogenase C, c-MYC MYC proto-oncogene, bHLH transcription factor, SRSF10 Serine and arginine rich splicing factor 10, MDM4 MDM4 regulator of p53, BCL-XL B-cell lymphoma-extra large, ANLN Anillin actin binding protein, EZR Ezrin, FFA Free fatty acid(s), PI3K-AKT-mTOR Phosphoinositide 3-kinase - AKT serine/threonine protein kinase - mechanistic target of rapamycin kinase, SNRPA1 Small nuclear ribonucleoprotein polypeptide A’, MPHOSPH6 M-phase phosphoprotein 6, POLDIP3 DNA polymerase delta interacting protein 3, RB1 RB transcriptional corepressor 1, AHNAK AHNAK nucleoprotein, MAGOHB Mago homolog B, exon junction complex subunit, CALM1 Calmodulin 1, p300 EP300 lysine acetyltransferase, HDAC Histone deacetylase, SIRT Sirtuin, PFKP Phosphofructokinase, platelet, LDHB Lactate dehydrogenase B, CCL18 C-C motif chemokine ligand 18, PD-L1 Programmed cell death 1 ligand 1, PTEN Phosphatase and tensin homolog, DCBLD1 Discoidin, CUB and LCCL domain containing 1, G6PD Glucose-6-phosphate dehydrogenase, PPP1R14B Protein phosphatase 1 regulatory inhibitor subunit 14B, HPV16 E6 Human papillomavirus type 16 early protein 6, PPP Pentose phosphate pathway, GPD2 Glycerol-3-phosphate dehydrogenase 2, CD86 Cluster of differentiation 86, iNOS Inducible nitric oxide synthase, CD206 Cluster of differentiation 206 (macrophage mannose receptor), HIF-1α Hypoxia-inducible factor 1 subunit alpha, GSH Glutathione, NADPH Nicotinamide adenine dinucleotide phosphate, ROS Reactive oxygen species, CD8+ T cells Cluster of differentiation 8 positive T lymphocytes, 2-DG 2-deoxy-D-glucose, USP39 Ubiquitin specific peptidase 39, GLUT-1 Glucose transporter type 1, HK2 Hexokinase 2 Current evidence on protein Klac modifications in prevalent female malignancies H4K12lac [55, 60]; H3K18lac[59]; SLFN5[60]; CCR7, IGFBP6, NDUFAF6[57] ACAA2[87] KCNK1[59], LDHA[59]; DCA/sodium oxamate[60]; LDHC4[61] c-MYC/SRSF10/MDM4-FL/BCL-XL [58]; ANLN/EZR/stiffness/adhesion[59]; SLFN5[60] ACAA2/FFA/Cell cycle/PI3K-AKT-mTOR-medicated autophagy[61] TEM Tumor microenvironment, Klac Lysine lactylation, H4K12lac Histone H4 lysine 12 lactylation, H3K18lac Histone H3 lysine 18 lactylation, SLFN5 Schlafen family member 5, CCR7 C-C motif chemokine receptor 7, IGFBP6 Insulin like growth factor binding protein 6, NDUFAF6 NADH Ubiquinone oxidoreductase complex assembly factor 6, ACAA2 Acetyl-CoA acyltransferase 2, KCNK1 Potassium two pore domain channel subfamily K member 1, LDHA Lactate dehydrogenase A, DCA Dichloroacetate, LDHC Lactate dehydrogenase C, c-MYC MYC proto-oncogene, bHLH transcription factor, SRSF10 Serine and arginine rich splicing factor 10, MDM4 MDM4 regulator of p53, BCL-XL B-cell lymphoma-extra large, ANLN Anillin actin binding protein, EZR Ezrin, FFA Free fatty acid(s), PI3K-AKT-mTOR Phosphoinositide 3-kinase - AKT serine/threonine protein kinase - mechanistic target of rapamycin kinase, SNRPA1 Small nuclear ribonucleoprotein polypeptide A’, MPHOSPH6 M-phase phosphoprotein 6, POLDIP3 DNA polymerase delta interacting protein 3, RB1 RB transcriptional corepressor 1, AHNAK AHNAK nucleoprotein, MAGOHB Mago homolog B, exon junction complex subunit, CALM1 Calmodulin 1, p300 EP300 lysine acetyltransferase, HDAC Histone deacetylase, SIRT Sirtuin, PFKP Phosphofructokinase, platelet, LDHB Lactate dehydrogenase B, CCL18 C-C motif chemokine ligand 18, PD-L1 Programmed cell death 1 ligand 1, PTEN Phosphatase and tensin homolog, DCBLD1 Discoidin, CUB and LCCL domain containing 1, G6PD Glucose-6-phosphate dehydrogenase, PPP1R14B Protein phosphatase 1 regulatory inhibitor subunit 14B, HPV16 E6 Human papillomavirus type 16 early protein 6, PPP Pentose phosphate pathway, GPD2 Glycerol-3-phosphate dehydrogenase 2, CD86 Cluster of differentiation 86, iNOS Inducible nitric oxide synthase, CD206 Cluster of differentiation 206 (macrophage mannose receptor), HIF-1α Hypoxia-inducible factor 1 subunit alpha, GSH Glutathione, NADPH Nicotinamide adenine dinucleotide phosphate, ROS Reactive oxygen species, CD8+ T cells Cluster of differentiation 8 positive T lymphocytes, 2-DG 2-deoxy-D-glucose, USP39 Ubiquitin specific peptidase 39, GLUT-1 Glucose transporter type 1, HK2 Hexokinase 2 Klac and Female-Prevalent malignancies Breast, ovarian, cervical, and endometrial cancers pose formidable challenges to global public health due to their considerable disease impact and elevated mortality risks [1–4, 6]. The current therapeutic landscape for these malignancies is complex and subtype-dependent. For early-stage breast cancer, primary treatment involves surgery combined with radiotherapy, endocrine therapy (ER/PR-positive), and targeted therapy (HER2-positive) [36, 37]. In advanced breast cancer, treatment strategies vary substantially by molecular subtype: hormone receptor-positive disease typically involves endocrine therapy combined with CDK4/6 inhibitors; HER2-positive cases utilize anti-HER2 targeted therapies including antibody-drug conjugates; while triple-negative breast cancer (TNBC) may employ chemotherapy, immunotherapy, or PARP inhibitors in BRCA-mutant cases [38, 39]. Ovarian cancer exhibits the highest mortality among gynecologic malignancies (5-year survival rates remain below 50%) [5], with standard therapy comprising cytoreductive surgery combined with platinum-based chemotherapy; PARP inhibitor maintenance therapy benefits BRCA-mutated patients [40]. While CA125 lacks sufficient diagnostic sensitivity for ovarian cancer [41], combining HE4 with the ROMA index improves diagnostic accuracy [42, 43], yet more specific early biomarkers are urgently needed. Cervical cancer incidence has declined significantly due to HPV vaccination campaigns, with early-stage disease managed by surgery or radiotherapy and advanced cases treated with bevacizumab plus chemotherapy [44–46]. Immune checkpoint inhibitors are used for PD-L1–positive cervical cancer, yet response rates remain modest [47]. Endometrial cancer staging relies on surgical evaluation, with molecular profiling (POLE mutations and mismatch repair [MMR] deficiencies) guiding prognosis and immunotherapy selection [48, 49]. Circulating tumor DNA (ctDNA) analysis of microsatellite instability (MSI) and PIK3CA mutations enables dynamic monitoring of recurrence in endometrial cancer, though sensitivity limitations persist [50, 51]. Thus, the development of robust diagnostic biomarkers and therapeutic targets remains imperative. Klac is a form of posttranslational modification that targets both histone and nonhistone proteins, and it plays a fundamental role in a range of cellular processes, including cell fate determination, signal transduction, gene expression, and metabolic regulation [13, 19, 24, 26, 27, 31]. Within the TEM, histone Klac directly links glycolytic activity to epigenetic regulation, modulating immune responses (e.g., macrophage M2 polarization), metastasis, and drug resistance [27, 52]. For instance, Klac enhances the immunosuppressive activity of tumor-associated macrophages (TAMs) and influences chemotherapy resistance by modifying DNA repair proteins such as NBS1 [53, 54]. By integrating metabolic signaling with epigenetic reprogramming, Klac provides a novel mechanistic foundation for tumor adaptation and therapeutic evasion. Emerging evidence underscores its functional significance in female-prevalent malignancies. Table 1 synthesizes key advancements in Klac biology specific to these malignancies. Breast cancer Protein Klac has yielded significant advances in breast cancer research. Prognostically, multiple studies validate the clinical relevance of Klac in diagnosis and survival prediction. Our group pioneered the characterization of Klac profiles in TNBC, demonstrating that histone H4K12lac is highly expressed in TNBC and independently predicts poor overall survival, suggesting its utility as a nuclear biomarker for TNBC stratification [55]. Additional prognostic models, including Cox risk scores based on lactylation-associated genes, and XGBoost-optimized lncRNA risk scores linked to Klac have shown robust predictive accuracy for breast cancer outcomes [56, 57]. Mechanistically, lactylation-driven tumor progression involves multifaceted pathways: (1) Metabolic-epigenetic crosstalk: lactate, a tumor metabolite, coordinates histone lactylation-dependent upregulation of c-MYC, driving SRSF10 expression to modulate MDM4 and BCL-X alternative splicing, thereby accelerating tumorigenesis [58]; (2) Ion channel regulation: The potassium channel protein KCNK1 activates lactate dehydrogenase A (LDHA), enhancing glycolysis, lactate production, and H3K18lac to promote proliferation and metastasis [59]; and (3) Transcriptional silencing: Histone H4K12lac suppresses SLFN5 expression, facilitating TNBC progression via impaired tumor-suppressive signaling [60]. Our study uncovers that LDHC4 drives TNBC progression by promoting K214lac of ACAA2, which activates fatty acid metabolism; the resulting free fatty acid accumulation stimulates autophagy and accelerates cell cycle, fueling tumor growth; as both a prognostic indicator and metabolic regulator, LDHC4 establishes a novel Klac-mediated oncogenic pathway, positioning the ACAA2/K214lac-fatty acid axis as a promising therapeutic target for TNBC [61]. Within the TME, protein Klac correlates with poor prognosis and critically influences immune evasion, drug resistance, and immunotherapy response [57]. Klac-specific gene signatures associate with immune cell infiltration, tumor mutational burden (TMB), and immune checkpoint expression (e.g., PD-L1, CTLA-4), revealing potential therapeutic targets [24, 56, 62]. Despite these advances, limitations persist, including small cohort sizes in exploratory studies, incomplete mechanistic insights, and the need for experimental validation of database-derived findings. Future studies should prioritize expanding cohorts, elucidating lactylation’s molecular underpinnings, and rigorously validating biomarkers and therapeutic targets to advance precision oncology in breast cancer. Ovarian cancer Protein Klac has garnered increasing attention in ovarian cancer research, offering novel insights into diagnosis, prognosis, and therapeutic strategies. Studies have demonstrated that Klac-associated genes enable effective risk stratification and prognostic prediction in patients with ovarian cancer [63–65]. Analysis of TCGA-OC data identified key Klac-related genes, with KEGG pathway enrichment revealing their critical roles in ovarian carcinogenesis through specific signaling mechanisms [63]. Risk stratification based on these genes categorized patients into subgroups with distinct gene expression profiles, and immune activity [64, 65]. Prognostic models incorporating Klac signatures exhibited robust predictive accuracy, highlighting the interplay between Klac, tumor classification, and immune regulation [63, 65]. Notably, histone H3K18 lactylation (H3K18lac) is closely linked to epithelial ovarian cancer progression [66]. Tumor tissues exhibit elevated H3K18lac levels compared to normal tissues, with higher levels correlating with worse overall survival, reduced progression-free survival, advanced pathological staging, and enhanced cancer cell migration [66]. Plasma lactate levels in ovarian cancer patients correlate with prognosis and molecular features [67]. Lactate promotes macrophage M2 polarization by upregulating CCL18, thereby driving tumor cell proliferation and migration and accelerating tumor growth and metastasis, as confirmed by in vivo studies [68]. Additionally, PFKP Klac has been shown to promote ovarian cancer progression via PTEN targeting [69], while Tanshinone I suppresses tumor growth and remodels the TEM by reprogramming glycolytic metabolism and modulating H3K18lac [70]. In immune evasion, LDHB-mediated histone lactylation activates PD-L1 expression, facilitating immune escape: LDHB knockout suppresses metabolic activity in ovarian cancer cells and enhances T cell-mediated cytotoxicity; mechanistically, LDHB regulates H3K18lac at the PD-L1 promoter to drive its expression, thereby impairing antitumor immunity [66]. These findings underscore Klac’s multifaceted role in ovarian cancer biology, though further validation in larger cohorts and mechanistic elucidation are warranted to translate these discoveries into clinical applications. Cervical cancer Research on Klac modifications in cervical cancer has yielded notable advancements. Meng et al. identified a novel Klac pattern (L-lactate group modification) on DCBLD1, highlighting its critical role in promoting tumor progression [71]. Their study demonstrated that L-lactate acts as a signaling molecule to stabilize DCBLD1 expression, while inhibiting G6PD enzymatic activity may mitigate DCBLD1’s oncogenic effects [71]. In HPV16-associated cervical cancer, Meng et al. revealed that HPV16 E6 promotes tumor cell proliferation by suppressing G6PD-K45 lactylation (G6PD-K45lac), offering a potential therapeutic strategy for HPV-related malignancies [72]. A comprehensive profiling of lysine-lactylated proteins in HeLa cells enabled cervical cancer stratification into distinct clusters with divergent prognoses; prognostic models derived from Klac-associated genes showed robust predictive accuracy, with PPP1R14B-K140lac emerging as a potential therapeutic target linked to cancer cell behavior [73]. Additionally, histone Klac is implicated in cervical carcinogenesis. Increased levels of H3K18lac and M2 macrophage infiltration are correlated with malignant progression. Crucially, lactate was found to enhance GPD2 expression via H3K18lac, and GPD2 knockdown reversed M2 polarization, establishing that pathway as a new target for precision therapy [52]. Endometrial cancer Recent investigations by Wei et al. [74] have identified significantly increased global protein Klac, with prominent enrichment at H3K18lac, in endometrial carcinoma tissues. Their experimental studies demonstrated that glycolysis inhibitors (2-deoxy-D-glucose [2-DG] and oxamate) effectively reduced intracellular protein Klac, resulting in inhibition of cancer cell proliferation and migration, induction of apoptosis, and cell cycle arrest in endometrial carcinoma cells [74]. Subsequent in vivo experiments corroborated these findings, showing that reduced Klac significantly suppressed tumor growth (as evidenced by decreased tumor volume and weight) and metastatic progression. The researchers also observed elevated USP39 expression in endometrial carcinoma specimens [74]. Functional studies revealed that USP39 knockdown inhibited cancer cell proliferation and migration, while USP39 overexpression counteracted 2-DG’s antitumor effects, indicating a potential mechanistic connection between lactylation and USP39-mediated oncogenesis [74]. These collective findings highlight the critical role of protein Klac in endometrial carcinoma progression and its therapeutic implications. Molecular mechanisms of Klac in the progression of Female-Prevalent malignancies Protein Klac modifications significantly contribute to the pathogenesis of breast and gynecologic cancers by modulating multiple oncogenic processes. These include transcriptional regulation, metabolic adaptation, immune microenvironment remodeling, and promotion of malignant phenotypes such as tumor cell proliferation, migration, and invasive capacity. Klac-modulating proteins/pathways are summarized in Table 1. Regulation of gene expression Lactate levels modulate histone Klac status, thereby regulating the expression of critical genes that govern tumor cell behavior. Studies demonstrate that H3K18lac significantly enriches promoter regions of tumor-associated genes and correlates with their expression levels [75]. For instance, in breast cancer, elevated expression of the oncogene c-MYC is closely linked to malignant progression: H3K18lac enrichment at the c-MYC promoter (− 70 to + 3 region) enhances its transcriptional activity, driving c-MYC overexpression and subsequent tumor aggression [58]. In endometrial cancer, H3K18lac enrichment at the USP39 promoter drives its transcription, and that this histone Klac-mediated upregulation of USP39 promotes tumor growth by stabilizing glycolytic enzymes to enhance glycolysis [74]. Similarly, in ovarian cancer, H3K18lac enrichment at the CCL18 promoter upregulates this chemokine, which induces M2 macrophage polarization in the TEM, accelerating proliferation and metastasis [68]. Elevated Klac levels also indirectly regulate gene expression by activating specific signaling pathways. For example, H3K18lac promotes USP39 transcription, leading to the stabilization of the glycolytic enzyme PGK1, which subsequently activates the PI3K/AKT pathway [74]. This cascade enhances HIF-1α expression, which drives oncogenic pathways by upregulating genes for glycolysis and survival, thereby fueling endometrial cancer cell proliferation and migration [74]. In breast cancer, H3K18lac enrichment at the c-MYC promoter upregulates c-MYC, which subsequently binds to the SRSF10 promoter to enhance its transcription. SRSF10-mediated alternative splicing of MDM4 and BCL-X generates pro-survival isoforms (e.g., MDM4-FL and BCL-XL), promoting tumor cell proliferation and invasion [58]. Collectively, histone Klac critically regulates gene expression by enriching at promoter regions of key genes (e.g., c-MYC, USP39, CCL18), enhancing transcription, and activating oncogenic pathways. These mechanisms drive tumor initiation and progression, as summarized in Fig. 2. Mechanistic basis of Klac in regulating gene expression and downstream pathways. This is exemplified by histone H3K18lac and non-histone protein ACAA2-K214lac, respectively. H3K18lac enriches at the promoter region of the c-Myc gene and activates its expression. Moreover, H3K18lac promotes USP39 transcription, leading to stabilization of the glycolytic enzyme PGK1, which in turn activates the PI3K/AKT pathway. For non-histone Klac, ACAA2-K214lac activates fatty acid (FA) metabolism. The resulting accumulation of free fatty acids (FFAs) stimulates autophagy and accelerates the cell cycle, thereby fueling tumor growth [61]. Together, these mechanisms collectively promote the progression of female-specific malignancies. Klac Lysine lactylation, ACAA2-K214lac Acetyl-CoA acyltransferase 2 lysine 214 lactylation, c-Myc MYC proto-oncogene, bHLH transcription factor, USP39 Ubiquitin specific peptidase 39, PGK1 Phosphoglycerate kinase 1, PI3K Phosphoinositide 3-kinase, AKT AKT serine/threonine protein kinase, mTOR mechanistic target of rapamycin kinase, LC3 Microtubule associated protein 1 light chain 3 alph, p62 sequestosome-1, CDK Cyclin-dependent kinase Impact on tumor cell metabolic reprogramming Glycolysis serves as the energetic foundation for rapid cancer cell growth, driving tumor proliferation by converting glucose into energy and biosynthetic precursors [76]. In endometrial cancer, histone Klac promotes glycolysis through a multi-tiered molecular mechanism: it enhances glycolytic activity by regulating USP39 expression. As a deubiquitinase, USP39 specifically interacts with the glycolytic enzyme PGK1 (validated by co-immunoprecipitation coupled with mass spectrometry), stabilizing PGK1 protein levels via deubiquitination [74]. Stabilized PGK1 activates the PI3K/AKT/HIF-1α signaling pathway, markedly upregulating the expression of glycolysis-related genes such as GLUT-1, HK2, and LDHA, thereby accelerating lactate production [74]. Experimental evidence confirms that inhibiting histone Klac reduces PI3K, p-PI3K, AKT, p-AKT, and HIF-1α levels, decreases lactate generation, and suppresses tumor proliferation. Conversely, USP39 overexpression enhances phosphorylation of these proteins, significantly promoting glycolysis and tumor growth [74]. In ovarian cancer, PFKP-K392lac regulates glycolytic homeostasis by targeting PTEN [69]. PFKP is highly expressed in ovarian cancer tissues and cells (further induced under hypoxic conditions). Knockdown of PFKP suppresses glycolytic activity in OV90 and SKOV3 cells and alleviates hypoxia-induced glycolytic enhancement [69]. Mechanistic study reveals that PFKP deletion upregulates PTEN levels in hypoxia-treated ovarian cancer cells, while PTEN inhibitors reverse the glycolytic inhibition caused by PFKP knockdown, confirming PFKP’s role in maintaining glycolysis via negative regulation of PTEN [69]. In cervical cancer, L-lactate activates HIF-1α transcription to regulate DCBLD1 expression, which in turn activates the pentose phosphate pathway (PPP) to promote lipid/DNA synthesis and reduce reactive oxygen species (ROS) accumulation, thereby driving tumor progression [71]. DCBLD1 knockdown significantly reduces PPP metabolite levels, inhibits lipid/DNA synthesis, increases ROS accumulation, and ultimately suppresses cervical cancer cell proliferation, migration, and invasion [71]. However, our group has also revealed a role for Klac in regulating fatty acid (FA)-related metabolic reprogramming in TNBC [61]. Specifically, we discovered that LDHC4 promotes TNBC progression by enhancing K214 lactylation of ACAA2 (ACAA2-K214lac), which in turn activates FA metabolism. The resulting accumulation of free fatty acids (FFAs) stimulates autophagy and accelerates the cell cycle, thereby fueling tumor growth [61]. Functioning as both a prognostic indicator and a metabolic regulator, LDHC4 establishes a novel lactylation-driven oncogenic pathway [61]. These findings position the LDHC4–ACAA2–FA axis as a promising therapeutic target for TNBC. In summary, glycolysis- or FA-driven epigenetic remodeling, mediated by histone and/or metabolic enzyme Klac, establishes a pro-tumor metabolic network across breast, endometrial, ovarian, and cervical cancers. This network drives tumor progression by stabilizing key enzymes, activating oncogenic pathways, and reprogramming metabolic flux (Fig. 2). Regulation of tumor immune evasion and immune cell function Emerging evidence reveals that lactate-mediated Klac serve as a pivotal mechanism for immune escape across cancer types. In ovarian cancer, LDHB-mediated histone Klac promotes immune evasion via epigenetic mechanisms: LDHB knockout significantly inhibits tumor cell growth, glucose uptake, lactate production, and ATP synthesis while enhancing T cell cytotoxic activity (elevated IL-2, TNF-α, IFN-γ, granzyme B, and perforin levels) [66]. Chromatin immunoprecipitation (ChIP) assays confirm that LDHB regulates H3K18lac at the PD-L1 promoter to enhance its expression [66]. PD-L1 overexpression reverses the immune-activating effects of siLDHB, indicating that lactylation promotes immune escape through PD-L1-mediated checkpoint mechanisms [66]. In cervical cancer, lactate accumulation elevates H3K18lac in macrophages, promoting M2 polarization (marked by CD86/iNOS downregulation and CD206/Arg-1 upregulation) via a GPD2-dependent mechanism to drive tumor progression [52]. Breast cancer studies reveal significant correlations between lactylation-associated genes (e.g., CCR7, IGFBP6, NDUFAF6) and immune cell infiltration features (e.g., mast cell quiescence, activated CD4+ memory T cells, M2 macrophage polarization), suggesting that Klac may remodel the TEM by modulating immune cell functions [57]. Collectively, these findings establish lactate-driven histone Klac as a conserved immunosuppressive program across ovarian, cervical, and breast cancers, which promotes immune evasion and tumor progression through PD-L1 upregulation, M2 macrophage polarization, and altered immune cell infiltration. Impact on tumor cell proliferation, migration, and invasion The interplay between metabolic reprogramming and epigenetic modification directly governs the malignant phenotypes of cancer cells across various gynecological cancers. In endometrial cancer, the inhibition of histone Klac via 2-DG and oxamate treatment significantly reduces tumor cell proliferation, induces cell cycle arrest at the G0/G1 to S phase transition, and triggers apoptosis. Critically, the anti-proliferative effects of 2-DG are reversed by overexpressing USP39, a downstream target of lactylation, thereby confirming its essential role in promoting tumor cell growth [74]. In breast cancer, KCNK1 promotes cell proliferation by activating LDHA and upregulating H3K18lac level [59]. In vitro and in vivo experiments demonstrate that KCNK1 overexpression enhances cell proliferation and lung metastasis (increased tumor volume/weight in nude mice), whereas KCNK1 knockdown suppresses these phenotypes [59]. In cervical cancer, DCBLD1 overexpression promotes cell proliferation, migration, and invasion by augmenting pentose phosphate pathway (PPP) activity, whereas its knockdown effectively suppresses these malignant behaviors [71]. In ovarian cancer, lactate-activated M2 macrophages promote OV cell migration via a Gpr132-dependent mechanism, which is blocked by Gpr132 knockdown [68]. Our study systematically evaluated ACAA2 and its lactylated form (ACAA2-K214lac) as therapeutic targets in TNBC [61]. Through computational screening combining molecular docking and dynamics simulations, we identified Lotamilast and Fumagillin as the optimal binders for wild-type ACAA2 and ACAA2-K214lac, respectively [61]. In vivo studies using orthotopic TNBC models revealed that both treatments significantly suppressed tumor growth compared to the control group, with no significant difference between them [61]. Mechanistically, IHC analysis confirmed a pronounced reduction in the proliferation marker Ki-67 and ACAA2 expression in both treatment groups, supporting ACAA2 and ACAA2-K214lac as promising therapeutic targets for TNBC [61]. Collectively, these findings underscore that lactylation-driven pathways not only fundamentally promote oncogenic processes but also present a promising avenue for targeted cancer therapy. While Klac inhibitors may act synergistically with established therapies such as chemotherapy and immunotherapy, this potential has yet to be established and merits comprehensive study. Summary and perspectives This review systematically summarizes the mechanistic roles and research advances of Klac in female-prevalent malignancies, highlighting its clinical potential for diagnosis, prognosis, and therapy. As an emerging PTM, Klac exerts central roles in gynecologic tumorigenesis and prognosis by regulating gene expression, metabolic reprogramming, immune microenvironment remodeling, and malignant phenotypes. With advancing mechanistic insights and technological innovations, Klac holds promise as a novel biomarker and therapeutic target for gynecologic cancers. Current research faces the following major challenges: (1) The dynamic nature of Klac makes it difficult to detect with current mass spectrometry, which is unable to track its real-time changes [77]; (2) Interindividual variations in genetic background, metabolic status, and environmental factors hinder personalized medical applications of Klac [34, 78]; (3) Non-histone Klac involves complex metabolic enzyme/signaling networks that are technically challenging to dissect [22, 79]. Mechanistic studies confront dual paradoxes: Klac exhibits both pro- and anti-tumor effects [54, 80, 81], and its crosstalk with phosphorylation, acetylation, and other modifications remains poorly defined [15, 22, 82, 83]; and (4) non-histone Klac’s roles in metabolic enzyme activity and signaling pathway regulation require deeper exploration [22, 84]. Additionally, technical challenges remain in achieving site-specific lactylation mimetics and developing cheap and high-throughput detection methods for lactylated proteins. Future research should prioritize: (1) Mechanistic elucidation: Deciphering histone and non-histone Klac functions. While histone Klac (e.g., H3K18lac) is known to modulate chromatin structure and transcription factor activity in oncogene regulation [85, 86], its tumor-specific networks in gynecologic cancers need systematic characterization. Non-histone Klac’s roles in metabolic reprogramming and signaling require further investigation. (2) Modification crosstalk: Resolving cooperative/competitive interactions between Klac and other post-translational modifications (e.g., phosphorylation, acetylation), particularly at shared histone residues; and (3) Clinical translation: Significant preclinical efforts are currently underway to develop targeted therapies against Klac-high tumors. These include optimizing lactate synthesis inhibitors (e.g., 2-DG, oxamate) to modulate Klac levels, designing small molecules that specifically target histone Klac sites, and establishing robust Klac-based prognostic models and biomarkers for patient stratification. While clinical translation remains in early stages, several drug development programs are exploring the therapeutic potential of Klac inhibition, focusing particularly on compound specificity, bioavailability, and safety profiles. Future directions should emphasize advancing these promising candidates into clinical trials to validate their efficacy and safety in cancer patients. In conclusion, Klac research demands integration of multi-omics technologies and clinical resources to overcome mechanistic and technical barriers, ultimately bridging the gap between basic science and clinical application. Acknowledgements We gratefully acknowledge the assistance in literature collection provided by Xiaolin Gong, Mengxi Cai, Le Zhou, Jiayun Lin, and Yan Qin (Innovation Team, Fujian Medical University). Abbreviations 2-deoxy-D-glucose acetyl-CoA acyltransferase 2 lysine 214 lactylation acetyl-CoA synthetase 2 AKT serine/threonine protein kinase cyclin-dependent kinase chromatin immunoprecipitation MYC proto-oncogene, bHLH transcription factor coenzyme A circulating tumor DNA histone H3 lysine 18 lactylation histone acetyltransferases lysine acetyltransferase 2 A lysine lactylation microtubule associated protein 1 light chain 3 alpha lactate dehydrogenase lactate dehydrogenase A low- and middle-income regions mechanistic target of rapamycin kinase microsatellite instability EP300 lysine acetyltransferase sequestosome-1 phosphoglycerate kinase 1 phosphoinositide 3-kinase pentose phosphate pathway post-translational modification tumor-associated macrophages tumor mutational burden tumor microenvironment triple-negative breast cancer ubiquitin specific peptidase 39 Authors’ contributions Zhaolei Cui and Yingying Lin conceived and designed the study. Chen Sun wrote the manuscript, and Dan Hu and Wei Peng helped to proof the manuscript. Zhaolei Cui and Yingying Lin proofread, revised and final approved the manuscript. All authors approved the final version of the manuscript. Funding This study was sponsored by the Joint Funds for the Innovation of Science and Technology, Fujian province (Grant numbers: 2021Y9221, 2021Y9222, and 2023Y9436), the Provincial Natural Science Fund of Fujian (Grant number: 2025J01212), the First Batch of High-level Talent Training Program of Fujian Cancer Hospital (Grant number: 2022YNG18), and Student Innovation Project of Fujian Medical University (Grant number: C2025207). Data availability The data that support the results of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This is a review article, and it did not involve direct contact with human participants or the collection of personal health information. Therefore, no ethical approval or informed consent was required. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Cheng Sun, Dan Hu and Wei Peng Co-First authors. Contributor Information Zhaolei Cui, Email: cuileidizi@fjmu.edu.cn. Yingying Lin, Email: linyingying226121@fjmu.edu.cn. References Associated Data Data Availability Statement The data that support the results of this study are available from the corresponding author upon reasonable request.